Use of informative prior distributions from mepolizumab data to support depemokimab PKPD model analysis

PKPD model for blood eosinophil count in eosinophilic indications

Catalina Barceló¹, Lénaïg Tanneau¹, Chayan Acharya¹, Jakob Ribbing¹, Chiara Zecchin², Stein Schalkwijk² ¹Pharmetheus AB, Uppsala, Sweden | ²GlaxoSmithKline, Stevenage, United Kingdom

Objective

To characterize the pharmacokinetic-pharmacodynamic (PKPD) relationship between depemokimab and blood eosinophil count, using informative prior distributions from a previous mepolizumab PKPD model.

Conclusions

- The depemokimab exposure-blood eosinophil count relationship was well characterized in mild-moderate asthma patients.
- Mepolizumab prior information efficiently supported prospective predictions of depemokimab exposure-response in other eosinophilic indications to be investigated.





Download poster including suppl. info. and glossary



Background


- Depemokimab is an anti-IL-5 monoclonal antibody that blocks IL-5 binding to its receptor and leading to a rapid reduction of the blood eosinophil count (BEC).
- Depemokimab showed enhanced affinity and extended half-life compared to first • in class mepolizumab and it is currently in Phase 3 development in severe eosinophilic asthma, CRSwNP, EGPA and HES.
- A previous mepolizumab model, developed on combined data from various \bullet eosinophilic conditions, and a wide range of baseline BEC and treatment regimens, was available to support depemokimab PKPD analysis.

Results

- Depemokimab exposure relationship with BEC data in mild-moderate asthma was well characterized by a placebo linear model plus an indirect response model with an inhibitory E_{max} function on k_{in} .
- E_{max} , EC_{50} and HL_{onset} were estimated to 89.2% (RSE 1.1%), EC_{50} 151 ng/mL (RSE 14.4%), and 20.8 hours (RSE 7.4%), respectively, in line with previous mepolizumab and depemokimab knowledge^{1,6}.
- Supporting priors were included to estimate or predict a) changes in baseline BEC, E_{max} and EC_{50} in patients with different eosinophilic conditions, b) the effect of predicted baseline BEC on E_{max} and EC_{50} , c) the changes in baseline BEC in the Asian population, and d) the effect of body weight on E_{max} .
- The supporting prior of age effect on EC_{50} , based on mepolizumab data, was not \bullet included in the final model because the estimated effect of age on EC_{50} for depemokimab data was significantly different from the one estimated with mepolizumab data (p<0.001).


Data and Methods

- Data from depemokimab first time in human (FTiH) study in mild-moderate asthma patients (NCT03287310): 727 BEC records from 48 patients¹.
- Depemokimab predicted plasma concentrations were first derived from a PK model developed on FTiH study data (not shown).
- The NWPRI prior subroutine in NONMEM was applied to support the estimation and prediction of covariate effects on a) baseline BEC, b) E_{max} and c) EC_{50} , using informative prior distributions from the wide-ranging mepolizumab analysis^{2,3}.
- The applicability of the supporting priors was evaluated using SCM + 3-5. Supporting priors on parameters where depemokimab data was significantly different from the mepolizumab prior distribution were removed.



- Based on the mepolizumab prior implementation, HES patients were predicted to have higher baseline BEC and EGPA patients to have a higher EC_{50} , compared to other patient populations (Figure 1).
- The estimated effect of the model-predicted baseline BEC on E_{max} and EC_{50} was modest in the limited range of values present in the analysis population. However, based on the mepolizumab prior, high baseline BEC could substantially impact the exposure response (Figure 2).
- Prospective predictions need to be confirmed with additional depemokimab data.

Figure 2. Exposure-response plot, where concentration is held constant, based on the final PKPD model and the typical baseline BEC for each patient population. Diamonds represent the range of model-predicted depemokimab concentrations for patients in the PKPD analysis data set.



Reference patient: 75.55 kg, White, Severe Asthma patient with baseline BEC of 320 cells/uL at baseline

and shaded area represent the parameter value for the reference patient and the 80%-125% margins relative to the reference subject, respectively.

¹Severe Asthma with screening BEC \geq 300 cells/µL;²Mild-Moderate Asthma with screening BEC \geq 200 ells/µL/no BEC inclusion criteria;⁴HES with screening BEC \geq 1000 cells/µL.

References

- [1] Singh D., et al. "A Phase 1 study of the long-acting anti-IL-5 monoclonal antibody GSK3511294 in patients with asthma". Br J Clin Pharmacol. 2021.
- [2] Gisleskog PO, et al. "Use of Prior Information to Stabilize a Population Data Analysis". J Pharmacokinet Pharmacodyn. 2002
- [3] Chan Kwong AHP, et al. "Prior information for population pharmacokinetic and pharmacokinetic/pharmacodynamic analysis: overview and guidance with a focus on the NONMEM PRIOR subroutine". J Pharmacokinet Pharmacodyn. 2020.

[4] Svensson RJ, Jonsson EN. "Efficient and relevant stepwise covariate model building for pharmacometrics". CPT Pharmacometrics Syst Pharmacol. 2022.

- [5] Brill MJ, et al. "Confirming model-predicted pharmacokinetic interactions between bedaquiline and lopinavir/ritonavir or nevirapine in patients with HIV and drug-resistant tuberculosis" Int J Antimicrob Agents. 2017.
- [6] Pouliquen IJ, et al. "Characterization of the relationship between dose and blood eosinophil response following subcutaneous administration of mepolizumab". Int J Clin Pharmacol Ther. 2015.

Disclosures

CB, LT, CA and JR are Pharmetheus employees; JR is a Pharmetheus shareholder; CZ and SC are GSK employees and shareholders.

Funding

Pharmetheus was funded by GSK to perform depemokimab PK and PKPD analysis based on FTiH data (GSK study 205722).

Contact catalina.barcelo@pharmetheus.com



Pharmetheus



Supplementary material

Use of informative prior distributions from mepolizumab data to support depemokimab PKPD model analysis

PKPD model for blood eosinophil count in eosinophilic indications

Catalina Barceló¹, Lénaïg Tanneau¹, Chayan Acharya¹, Jakob Ribbing¹, Chiara Zecchin², Stein Schalkwijk² ¹Pharmetheus AB, Uppsala, Sweden | ²GlaxoSmithKline, Stevenage, United Kingdom

Final PKPD model

- Placebo linear model with baseline and P_{slp} representing the proportional change over a year during treatment with placebo, plus a numerical (differential equation) solution describing an indirect response drugeffect on rate of formation, parameterized in terms of baseline, HL_{onset}, EC_{50} , E_{max} and HILL coefficient.
- Exponential IIV on baseline and RUV, and additive IIV on P_{slp} and logit- \bullet E_{max}

Model development with prior

- The PRIOR subroutine was used as an alternative to fixing parameters lacksquareto a previous estimate or pooling mepolizumab and depemokimab data to facilitate the estimation of selected depemokimab PKPD parameters, that were believed to be shared for mepolizumab and depemokimab, and where sufficient information was not available in the analysis data set^{3.}
- The prior point estimates and covariance matrix in NONMEM from the
- Exponential RUV implemented as additive on the log-scale

Covariate analysis

- The SCM procedure with adaptive scope reduction (ASR), SCM+, was used for the evaluation of covariate-parameter relationships^{1,2}. The forward selection and backward elimination p-values were, respectively, 0.01 and 0.001. Continuous covariate-parameter relationships were investigated as exponential models or linear models, on parameters without lower bound at zero, while categorical covariate-parameter relationships were implemented as a fractional difference to the most common category.
- Only one structural covariate-parameter relationship was evaluated. The effect of the predicted baseline BEC on the P_{slp} was not statistically significant (p>0.01), thus no covariate-parameter relationships were added to the model.

Model evaluation

Model evaluation was based on the inspection of RSE, plausibility of the parameter estimates, graphical diagnostics, including VPCs, as well as changes in the OFV provided by NONMEM.

- reference mepolizumab PKPD model were used to generate the NONMEM prior values, using the NWPRI subroutine^{3,4}. Prior values to fixed effects parameters were entered as a multivariate normal and their weight was informed by the covariance matrix. No prior information on the random effects parameters such as IIV and RUV were included in this analysis.
- Regarding fixed effects, the supporting prior covariates summarized in Table 1 were included to help the estimation or to allow for prospective predictions. Supporting priors on E_{max} and EC_{50} relative difference across patient populations were included in preparation for a model update with additional depemokimab data in various eosinophilic indications.

Evaluation of supporting priors

- The difference between depemokimab and mepolizumab populations in parameters implemented with priors was verified by testing a parameter of difference (THETA_{new}), estimated only on the new analysis data, on each of the model parameters implemented with prior, using SCM+ $(Equation 1)^{4-6}$.
- A significant improvement in OFV indicates that the parameter differs between depemokimab and mepolizumab population and thus, it is more appropriate to either remove the prior from the parameter or retain TUETA in the model

	THETA _{new} in the model.	THETA _{new} in the model.				
	Equation 1. Code implemented in SCM+.	Equation 1. Code implemented in SCM+.				
	$Parameter-Covariate = THETA_{pr}$	$Parameter-Covariate = THETA_{prior} * (1+THETA_{new}).$				
Table 1. Supporting prior covariates included in the depemokimab PKPD model development.						
Supporting prior covariate	Justification	Purpose				
 Mild-Moderate Asthma¹, EE or NP on Baseline HES² on Baseline EGPA on Baseline HV on Baseline 	Patient population not available in analysis data	Prediction				
Asian race on Baseline	Limited data available in analysis data	Prediction				
 Mild-Moderate Asthma³ on E_{max} 	Indirect estimation of E_{max} for the reference patient population (severe asthma)	Estimation				
 Predicted baseline BEC on E_{max} Body weight on E_{max} 	Limited range of covariate values in the analysis data	Estimation				
 Mild-Moderate Asthma³ on EC₅₀ 	Indirect estimation of EC $_{50}$ for the reference patient population (severe asthma)	Estimation				
 NP on EC₅₀ EGPA on EC₅₀ 	Patient population not available in analysis data	Prediction				
 Predicted baseline BEC on EC₅₀ Age on EC₅₀ 	Limited range of covariate values in the analysis data	Estimation				

Glossary



BEC	Blood eosinophil count	FTiH	First Time in Human	OFV	Objective function value
C_{trough}	Trough concentration	HES	Hypereosinophilic Syndrome	PK	Pharmacokinetic
CRSwNP	Chronic Rhinosinusitis with Nasal Polyposis	HL _{onset}	Half-life for drug on-/offset	PKPD	Pharmacokinetic-pharmacodynamic
E _{max}	Maximum effect	HV	Healthy volunteer	RSE	Relative standard error
EC ₅₀	Concentration at half maximum effect	IIV	Inter-individual variability	RUV	Residual unexplained variability
EE	Eosinophilic Espohagitis	NP	Nasal Polyposis	SCM	Stepwise covariate model building
EGPA	Eosinophilic Granulomatosis with Polyangiitis	NWPRI	Normal-inverse Wishart prior		procedure
				VPC	Visual Predictive Check

¹Severe Asthma with screening BEC \geq 300 cells/µL;²Mild-Moderate Asthma with screening BEC \geq 200 ells/µL/no BEC inclusion criteria;⁴HES with screening BEC \geq 1000 cells/µL.

References

- [1] Jonsson EN, et al. Pharm Res 1998; Sep; 15(9): 1463-8
- [2] Jonsson EN, et al. Presented at PAGE 2018, Montreux, Switzerland. Abstract 8429
- [3] Gisleskog PO, et al. "Use of Prior Information to Stabilize a Population Data Analysis". J Pharmacokinet Pharmacodyn. 2002
- [4] Chan Kwong AHP, et al. "Prior information for population pharmacokinetic and pharmacokinetic/pharmacodynamic analysis: overview and guidance with a focus on the NONMEM PRIOR subroutine". J Pharmacokinet Pharmacodyn. 2020
- [5] Svensson RJ, Jonsson EN. "Efficient and relevant stepwise covariate model building for pharmacometrics". CPT Pharmacometrics Syst Pharmacol. 2022.
- [6] Brill MJ, et al. "Confirming model-predicted pharmacokinetic interactions between bedaquiline and lopinavir/ritonavir or nevirapine in patients with HIV and drug-resistant tuberculosis". Int J Antimicrob Agents. 2017.

Disclosures

CB, LT, CA and JR are Pharmetheus employees; JR is a Pharmetheus shareholder; CZ and SC are GSK employees and shareholders.

Contact catalina.barcelo@pharmetheus.com

Funding

Pharmetheus was funded by GSK to perform depemokimab PK and PKPD analysis based on FTiH data (GSK study 205722).

